EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy United States Infants: A Randomized, Controlled Clinical Study

Debasish Saha, Laura Tomasi Cont, Nicola P Klein, Judith M Martin, Elisa Cinconze, Pavitra Keshavan, Luca Moraschini, Danielle Morelle, Mauro Trapani, Maria Lattanzi, Daniela Toneatto, James Campbell, Robert Clifford, Robyn Hartvickson, Teena Hughes, Nicola P Klein, Aarti Kulshrestha, Michael Leonardi, Gary Marshall, Judith M Martin, Michael Moore, Christopher Peltier, Walter Rok, Randall Schumacher, Shelly Senders, Leonard Weiner, Elisa Cinconze, Daniela Toneatto, Pavitra Keshavan, Maria Lattanzi, Luca Moraschini, Danielle Morelle, Debasish Saha, Laura Tomasi Cont, Mauro Trapani, Yamini Purna Bollu, Aparna Yarraguntla, and Keshaw Kumar

Open Forum Infectious Diseases · 2026-11-06

DOI: 10.1093/ofid/ofag709 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Meningococcal serogroup B (MenB) vaccine, 4CMenB, has been licensed in the United States (US) since 2015 for individuals aged 10–25 years. This study assessed 4CMenB in US infants when administered concomitantly with pneumococcal vaccine PCV13 and other routine infant vaccines (RIVs). Methods This phase 3b, observer-blind, placebo-controlled study (NCT03621670) randomized (2:1) healthy US infants to receive either 4CMenB administered concomitantly with PCV13 and other RIVs (N=786; 4CMenB+RIVs group) or placebo with PCV13 and other RIVs (N=409; Placebo+RIVs group) at 2, 4, 6, and 12 months of age. Primary objectives were to demonstrate the sufficiency of immune responses to MenB indicator strains (individually and combined), to demonstrate the non-inferiority of immune responses to PCV13 administered with 4CMenB+RIVs versus PCV13 plus placebo+RIVs, and assess safety. Immune responses to RIVs administered with 4CMenB+PCV13 versus RIVs plus placebo+PCV13 were investigated as secondary objectives. Results Pre-specified sufficiency criteria post-dose 3 and post-dose 4 were met for each MenB strain except NHBA and the composite response. Percentages of seroprotected participants (human serum bactericidal assay titers ≥lower limit of quantitation) against MenB indicator strains post-dose 4 were 86.1–99.6% in 4CMenB+RIVs group versus 0.0–2.8% in Placebo+RIVs group. The success criterion for achieving immunological non-inferiority of PCV13 was met, and concomitant 4CMenB administration did not adversely affect immune responses to other RIVs. 4CMenB co-administered with PCV13 and RIVs was generally well tolerated, with no safety concerns identified. Conclusions 4CMenB was well tolerated and immunogenic in US infants, producing no immunological interference when co-administered with other recommended vaccines.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →